SJ-01 is under clinical development by Shanghai Bao Pharmaceuticals and currently in Phase I for Anemia. According to GlobalData, Phase I drugs for Anemia have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SJ-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SJ-01 overview

SJ-01 is under development for the treatment of anemia.

Shanghai Bao Pharmaceuticals overview

Shanghai Bao Pharmaceuticals (Bao Pharma) is a pharmaceutical and drug development company. The company focuses on drug development and commercialization of recombinant protein drugs and antibody drugs. Its drug product lines include aqueous solution for injection, lyophilized powder for injection, and pre-filled disposable injection. Its service offering includes preclinical research, clinical trials, drug development, drug discovery programs, research and development, and warehousing services. The company provides drug development services in various therapeutic areas such as multi domain diseases, tumors, and anemia. Bao Pharma is headquartered in Shanghai, China.

For a complete picture of SJ-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.